Activated but functionally impaired memory Tregs are expanded in slow progressors to type 1 diabetes by Boldison, J et al.
ARTICLE
Activated but functionally impaired memory Tregs are expanded
in slow progressors to type 1 diabetes
Joanne Boldison1,2 & Anna E. Long3 & Rachel J. Aitken3 & Isabel V. Wilson3 & Clare Megson3 & Stephanie J. Hanna1 &
F. Susan Wong1 & Kathleen M. Gillespie3
Received: 22 June 2021 /Accepted: 26 August 2021
# The Author(s) 2021
Abstract
Aims/hypothesis Slow progressors to type 1 diabetes are individuals positive for multiple pancreatic islet autoantibodies who
have remained diabetes-free for at least 10 years; regulation of the autoimmune response is understudied in this group. Here, we
profile CD4+ regulatory T cells (Tregs) in a small but well-characterised cohort of extreme slow progressors with a median age 43
(range 31–72 years), followed up for 18–32 years.
Methods Peripheral blood samples were obtained from slow progressors (n = 8), age- and sex-matched to healthy donors. One
participant in this study was identified with a raised HbA1c at the time of assessment and subsequently diagnosed with diabetes;
this donor was individually evaluated in the analysis of the data. Peripheral blood mononuclear cells (PBMCs) were isolated, and
to assess frequency, phenotype and function of Tregs in donors, multi-parameter flow cytometry and T cell suppression assays
were performed. Unsupervised clustering analysis, using FlowSOM and CITRUS (cluster identification, characterization, and
regression), was used to evaluate Treg phenotypes.
Results Unsupervised clustering on memory CD4+ T cells from slow progressors showed an increased frequency of activated
memory CD4+ Tregs, associated with increased expression of glucocorticoid-induced TNFR-related protein (GITR), compared
withmatched healthy donors. One participant with a raised HbA1c at the time of assessment had a different Treg profile compared
with both slow progressors and matched controls. Functional assays demonstrated that Treg-mediated suppression of CD4+
effector T cells from slow progressors was significantly impaired, comparedwith healthy donors. However, effector CD4+ T cells
from slow progressors were more responsive to Treg suppression compared with healthy donors, demonstrated by increased
suppression of CD25 and CD134 expression on effector CD4+ T cells.
Conclusions/interpretations We conclude that activated memory CD4+ Tregs from slow progressors are expanded and enriched for
GITR expression, highlighting the need for further study of Treg heterogeneity in individuals at risk of developing type 1 diabetes.
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Introduction
Progression rates from the first appearance of pancreatic islet
autoantibodies to development of clinical symptoms of type 1
diabetes are well described in childhood, with 70% ofmultiple
islet autoantibody-positive children developing diabetes with-
in 10 years of seroconversion, which increases to 84% for
those followed for 15 years [1]. By contrast, the mechanisms
underlying adult-onset type 1 diabetes, which represents more
than half of clinical type 1 diabetes, are under-investigated.
A staging system is increasingly widely utilised [2] to
define progression to type 1 diabetes; individuals enter stage
1 at development of multiple islet autoantibodies, stage 2 with
dysglycaemia, and stage 3 at onset of symptoms. Some multi-
ple islet autoantibody-positive individuals, in stage 1 and 2,
progress more slowly and develop adult-onset type 1 diabetes.
We previously described a small but very well-characterised
group of extreme slow progressors [3] who remained
diabetes-free for at least 10 years after the first multiple islet
autoantibody sample was detected. Subsequently, we showed
that islet autoantigen-specific CD8+ T cell responses were
largely absent in slow progressors but were readily detectable
in individuals with recent-onset and longstanding diabetes [4].
This might suggest that regulation of the autoimmune
response is enhanced in these individuals comparedwith those
who progress.
Earlier studies have shown that, although regulatory T cells
(Tregs) appear to be normal in number, individuals with
diabetes have some functional defects, which include a
reduced capacity to respond to IL-2 [5]. In addition, effector
CD4+ T cells in those who develop diabetes may be more
resistant to regulation, demonstrated by a reduction in
suppression of effector T cells, by both naturally occurring
Tregs and by in vitro generated induced Tregs [6], and dimin-
ished IL-2 responsiveness in antigen-experienced CD4+ T
cells [7].
In the Bart’s Oxford (BOX) study, 14 of 36 (39%) slow
progressors developed diabetes during long-term follow-up
(median 19 years; IQR 15–26 years). The aim of this study
was to examine whether Treg function can be differentiated
from age- and sex-matched healthy donors in this well-
characterised cohort of extreme slow progressors (including
an individual who was diagnosed with diabetes after sampling
and 32 years follow-up).
Methods
Participants The BOX study is a longitudinal, population-
based study examining risk factors for type 1 diabetes in rela-
tives of individuals diagnosed under the age of 21 years [8].
We previously described the characteristics of long-term slow
progressors who remainedmultiple islet autoantibody positive
for more than 10 years but did not develop clinical symptoms
of diabetes; the Slow or Non progressive Autoimmunity to the
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Islets of Langerhans (SNAIL) cohort [3]. Subsequently, ten
slow progressors who continued to remain diabetes-free and
were willing to provide large-volume blood samples were
included in an analysis of T and B cell function [4]. In the
current study, eight slow progressors (SP group), with median
age 43 (range 31–72 years), had been islet autoantibody posi-
tive for between 18 and 32 years (electronic supplementary
material [ESM] Table 1). All participants have been at stage 1
of type 1 diabetes progression for significant lengths of time,
although some subsequently lost islet autoantibody positivity
for some antigens [4]; however one individual has been at
stage 2 for at least 6 years but has not developed clinical
symptoms (ID: SP 608), and one was diagnosed with diabetes
(ID: SP 606). The participant aged 72 years (ID: SP 606) was
identified with a raised HbA1c of 53 mmol/mol (7%) at the
time the experimental sample was taken. Genetic information
for each slow progressor is provided in ESM Table 2, includ-
ing level of genetic risk. All healthy donors (HD group) were
matching within ± 5 years.
Autoantibodies Autoantibodies were measured using well-
described radioimmunoassays [9]. The results were expressed
in units derived from in-house standard curves for insulin
autoantibodies (IAA) and zinc transporter 8 autoantibodies
(ZnT8A), measured in 5 μl and 2 μl of serum, respectively.
For GAD autoantibodies (GADA) and islet antigen-2 autoan-
tibodies (IA-2A), results were derived from a standard curve
developed for the NIDDK-sponsored Islet Autoantibody
Harmonization Program and were expressed in digestive and
kidney (DK) units/ml [10]. These assays were submitted to the
Islet Autoantibody Standardisation Programme 2020, where
they achieved sensitivity and specificity for GADA of 64%
and 97.8%; for IA-2A of 72% and 100%; for IAA of 60% and
97.8%; and for ZnT8A of 68% and 100% (when combining
results of variants as described), respectively.
Peripheral blood samples Slow progressor and matched
healthy donor samples were collected and processed on the
same day to avoid any technical batch effects. Peripheral blood
mononuclear cells (PBMCs) were isolated from heparinised
samples of whole blood via density gradient centrifugation
using Lymphoprep (STEMCELL Technologies, Cambridge,
UK). 1 × 106 fresh PBMCs were taken for CD4+ regulatory T
cell flow cytometric analysis. Remaining PBMCs were used
for CD4+ T cell suppression assays.
Flow cytometry Fresh PBMCs were incubated with TruStain
(anti-human CD16/32 [Biolegend, UK]) for 10 min at 4°C,
followed by fluorochrome-conjugated monoclonal antibodies
(mAbs) against cell surface markers for 30 min at 4°C. Multi-
parameter flow cytometry was carried out using mAbs
(Biolegend): CD19 BV605 (HIB19), CD8 BV605 (HIT8a),
CD4+ AF700 (A161A1), CD25 PeCy7 (BC96), CD127
PerCPCy5.5 (A019D5), CD45RO BV421 (UCHL1),
CD45RA APC-Cy7 (HI100), CD39 PE/DAZZLE 954 (A1),
lymphocyte-activation gene 3 (Lag-3) BV786 (11C3C65),
CD49b FITC (P1E6-C5), glucocorticoid-induced TNFR-
related protein (GITR) BV711 (108–17), HLA-DR BV650
(L243), forkhead box P3 (FOXP3) AF647 (206D), and cyto-
toxic T-lymphocyte-associated protein 4 (CTLA4) PE
(L3D10). Dead cells were excluded from analysis by
Live/Dead exclusion dye (Invitrogen, MA, USA). FOXP3
and CTLA4 intracellular staining was performed using the
eBioscience nuclear transcription kit. Cells were acquired on
LSRFortessa (FACS Diva software, BD Biosciences, UK),
and analysis was performed using FlowJo software, version
10.7 (Treestar, USA), and unsupervised clustering methods.
Unsupervised clustering using FlowSOM and CITRUS Initial
data processing was performed using FlowJo. A total of
10,000 events of live CD19−CD8−CD4+CD45RA− T cells
from each donor were down-sampled and imported into R
software, version 4.0, and the FlowSOM algorithm was used
[11]. Clusters were visualised using both a minimum spanning
tree (MST) and t-distributed stochastic neighbour embedding
(t-SNE) plots. Heatmaps were generated using R package
ggplot2. CITRUS (cluster identification, characterization and
regression) was performed using Cytobank [12]. Samples
were loaded in Cytobank and traditional gating performed
on live CD8−CD19−CD4+CD45RA− cells. Clustering was
performed using equal event sampling (8000) and a minimum
cluster size set to 1%. A false discovery rate (FDR) was 1%.
For both FlowSOM and CITRUS the following markers were
included: CD25, CD127, CD39, FOXP3, CTLA4, HLA-DR,
GITR, Lag-3 and CD49b.
CD4+ T cell suppression assay CD4+ T cells were isolated by
magnetic-activated cell sorting (MACS) using the
CD4+CD25+ T cell isolation kit (Miltenyi), according to the
manufacturer’s instructions. Briefly, CD4+ T cells, from
PBMCs, were negatively isolated. Total CD4+ T cells were
then separated into CD4+CD25− and CD4+CD25+ fractions
by positive selection using anti-CD25 microbeads
(CD4+CD25+ cells; purity >90%). CD4+CD25− (4 × 105/
well) responder cells were cultured with CD4+CD25+ at vari-
ous ratios indicated. All CD4+CD25− responder cells were
labelled with CFDA-SE (CFSE) (Invitrogen) prior to culture
set up. All co-cultures were stimulated with Dynabeads anti-
CD3/28 beads (Invitrogen) (0.35 μl beads/4 × 105 cells, 1
bead: 28 responders) and cultured for 3 days before analysis
by flow cytometry with CD4 AF700, CD25 PeCy7 and
CD134 APC. Dead cells were excluded from analysis by
Live/Dead exclusion dye (Invitrogen). All cells were cultured
in RMPI complete media containing 2 mmol/l L-glutamine,
100 U/ml penicillin and 10% heat-inactivated AB serum
(Sigma-Aldrich, UK). Percentage suppression was calculated
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by (%CFSE [or CD25/CD134] expression in responder T cell
[Tresponder] and Treg co-cultures)/(% CFSE [or
CD25/CD134] in Tresponder alone cultures) × 100.
Supernatants were taken from co-cultures at the 3-day
endpoint, to analyse IFNγ and IL-17A cytokines, which were
measured by a Meso Scale Discovery (MSD) (MA, USA)
system. MSD was performed according to the manufacturer’s
instructions and evaluated using anMSD Sector Imager 6000.
Statistics Statistical analyses were performed using GraphPad
Prism 8 (GraphPad Software, San Diego, CA, USA).
Significance was determined by two-way ANOVA, followed
by a Bonferroni post hoc test for Treg suppression assay
results, and Wilcoxon matched-pairs signed rank test was
performed to compare frequency and surface expression on
Treg clusters. Data were considered significant at p < 0.05.
Study approval The BOX study was approved by the South
Central–Oxford C National Research Ethics Committee. The
study of slow progressors and control individuals was
approved by the South East Wales Research Ethics
Committee and conducted in accordance with the principles
of good clinical practice established by the International
Council for Harmonization/WHO. All participants provided
written informed consent prior to enrolment, as mandated by
the Declaration of Helsinki.
Results
Slow progressors have significantly increased proportions of
CD4+ effector memory TregsWe investigated the frequency of
Tregs present in the peripheral blood of slow progressors (SP
group), compared with age- and sex-matched healthy donors
(HD group). We included both CD45RA and CD45RO
surface markers to identify resting Tregs and activated
Tregs, respectively. Overall, we found no differences in the
percentages of CD4+CD45RA+ naive and CD4+CD45RO+
memory compartments (ESM Fig. 1a). As Tregs are hetero-
geneous [13], we chose to employ unsupervised gating using
FlowSOM [11]. Surface markers used for analysis included
CD25, CD127, FOXP3, HLA-DR, CD39, CTLA4, GITR,
CD49b and LAG3, and FlowSOM clustering was performed
on down-sampled CD45RA− cells. CD45RA− T cells were
chosen because of low or absent expression of the above
Treg markers on naive T cells.
FlowSOM identified ten distinct clusters (Fig. 1a, MST),
which were identified as either a memory Treg or a memory T
cell, based on expression of key markers (Fig. 1b, heatmap).
CD4+ memory T cells and Tregs were each separated into five
clusters, characterised by individual phenotypes. Memory
Treg clusters 1–4 had an intermediate to high expression of
CD25 and FOXP3; however, CD39, HLA-DR and GITR
were expressed heterogeneously (Fig. 1b). All metaclusters
were expressed in each donor (ESM Fig. 1b) but memory T-
cell_4 and memory Treg_1, with a mean abundance of
<0.05%, were deemed irrelevant subsets (ESM Fig. 1c). To
show the relationship between clusters, t-SNE plots were
generated, overlaying each cluster identified for HD (Fig.
1c) and SP cohorts separately (Fig. 1d). t-SNE plots revealed
memory Treg subsets 3 and 4 clustered into distinct regions;
however, some other subsets such as memory T cell_2 and
memory T cell_3 did not form discrete populations and
appeared more dispersed, indicating that these smaller subsets
are part of a larger population.
Analysis of each cluster from our SP cohort revealed a
significant increase in memory Treg_3, compared with the
matched HD (p < 0.01) (Fig. 1f). Memory Treg_4 and
HLA-DR+GITR+ clusters also increased in individuals in the
SP group but did not reach statistical significance (Fig. 1g, h).
Donor SP 606 (Fig. 1e–g, orange dots) had an increase in
memory Tregs compared with the matched HD participant.
Interestingly, we found a modest but not significant decrease
in memory T-cell_1 cluster in the SP group compared with the
HD group (Fig. 1i), supporting our previous observations [4].
Predictive modelling confirmed that increased Treg frequen-
cy is a signature of slow progressors Following our FlowSOM
analysis, we confirmed our observations with conventional
hierarchical gating (Fig. 2a–f) and CITRUS (Fig. 2g–i).
Using hierarchical gating, we emulated our Treg FlowSOM
subsets, which were largely based on HLA-DR and GITR
expression (Fig. 2a). We revealed that six out of seven in the
SP group, including SP 606 (orange dot), had increased
CD4+CD45RA−CD25+CD127lo effector memory Tregs, and
this was significant (p = 0.023) when compared with the HD
counterparts (Fig. 2b). Further gating on CD39, followed by
Fig. 1 In-depth phenotypical analysis reveals that CD4+ Treg subtypes
are increased in the slow progressor cohort. Treg compartments generated
by FlowSOM, clustering on live CD4+CD45RA− cells from all donors.
Ten metaclusters were identified based on marker expression: memory T
cell_1; memory T cell_2; memory T cell_3; memory T cell_4; CD49b
memory T cell; HLA-DR+GITR+ memory T cell; memory Treg_1;
memory Treg_2; memory Treg_3; and memory Treg_4. (a) MST of ten
metaclusters generated using nine different Treg markers. Each node
represents a cluster (100 clusters) and larger metaclusters (10
metaclusters) are coloured around groups of nodes. Pie charts within
each node represent expression levels of individual markers. (b)
Heatmap with each metacluster to show overall marker expression. (c,
d) t-SNE maps generated for the HD group (c) and the SP group (d) with
overlays of each metacluster identified by FlowSOM. (e–l) Relative
abundance boxplots for each metacluster (>0.05% abundance)
identified for both HD and SP groups: memory Treg_2 (e), memory
Treg_3 (f), memory Treg_4 (g), HLA-DR+GITR+ memory T cell (h),
memory T cell_1 (i), memory T cell_2 (j), memory T cell_3 (k) and
CD49b memory T cell (l). Orange dots represents donor SP 606. **p <
0.01, Wilcoxon matched-pairs signed rank test. The key applies to figure
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FOXP3 expression (mean expression 90.71% [HD] and
89.01% [SP]), we observed increases in memory Treg_3
(HLA-DRintGITRlo) (p = 0.07) and memory Treg_4
(HLA-DRhiGITR+) subsets (p < 0.05) (Fig. 2d,e) in the
SP cohort; however, an overall increase in Tregs in donor
SP 606 (orange) was not evident. The frequency of Treg
populations (of interest) from both FlowSOM (Fig. 1) and
hierarchical gating (Fig. 2a–f) expressed as ratios for each
individual SP participant normalised to the matched HD
participant is shown in ESM Fig. 1d. No difference in
CD4+CD45RA+CD25+CD127lo resting Tregs between
groups was observed (ESM Fig. 1e). Furthermore, consis-
tent with previous reports [14], CD25+ Tregs increased with
age in our HD cohort (data not shown).
CITRUS is an algorithm that identifies different cell
signatures between grouped data [15] and provides
predictive modelling. Here, pre-gating was performed in
Cytobank and clustered with the same cellular markers as
our FlowSOM analysis. CITRUS analysis provides a
visualisation tree (Fig. 2g–i). Here, SP and HD groups
are clustered separately, based on marker expression;
CD127 (Fig. 2g), CD25 (Fig. 2h) and FOXP3 (Fig. 2i)
were used as an example to illustrate clustering of CD4+
memory Tregs. Comparing our cohorts, CITRUS identi-
fied two distinct clusters that were different in frequency
(Fig. 2j). Analysis of cluster phenotypes (Fig. 2k)
revealed a similar phenotype to memory Treg_3 and
memory Treg_4 metaclusters (FlowSOM; Fig. 1).
Overall, high-dimensional immunophenotyping confirmed
that slow progressors have an expanded population of
CD45RA−CD25+CD127lo Tregs, which were specifically
enriched for activated memory Tregs expressing FOXP3,
CD39, CTLA4, HLA-DR and GITR.
Increased expression of GITR on an activated memory Treg
population in slow progressors Next, we sought to determine
if the SP memory T cell metaclusters had different levels of
expression of Treg markers. Figure 3a,b shows expression
heatmaps, with each marker used for clustering on the eight
individual metaclusters, for both SP and HD cohorts, not
including donor SP 606. Overall, the heatmaps revealed no
striking differences in expression levels for each metacluster
in both groups; however, quantitative analysis demonstrated a
significant increase in GITR expression in the activated
memory Treg_4 metacluster (Fig. 3c,d). Interestingly, we
did not observe this GITR increase in donor SP 606,
compared with the matched HD donor (Fig. 3c,d, orange).
To confirm our observations, we analysed the expression of
GITR on the HLA-DRhiGITR+ population defined by hier-
archical gating. Similarly, we observed a significant
increase in GITR expression on this memory Treg popula-
tion (Fig. 3e,f). Gating on all CD39+FOXP3+ cells also
revealed a significant increase of GITR expression (data
not shown). Overall, differences in expression of other
markers were not observed; however, HLA-DR expression
was modestly increased in selected SP donors (ESM Fig.
2a), but this was not confirmed in all donors with hierarchi-
cal gating (ESM Fig. 2b). Expression for both GITR and
HLA-DR in memory Treg subsets in all donors, normalised
to the HD cohort, is shown in ESM Fig. 2c.
CD4+ Tregs from slow progressors show impaired suppressive
capacity To test the functionality of CD4+CD25+ Tregs in our
SP cohort we utilised a well-established in vitro T cell
suppression assay [16]. Treg-mediated suppression of CD4+
responder T cells (CD4+CD25− T cells) was investigated in
the SP and HD cohorts by proliferation and activation assays.
CD4+ responder T cells were labelled with CFSE, co-cultured
with varying ratios of CD4+ Tregs and stimulated with anti-
CD3/28 activation beads. For representative flow cytometric
plots, see ESM Fig. 3a.
First, we investigated autologous co-cultures to assess
overall differences in Treg functionality (Fig. 4a–d). Treg-
mediated suppression of CD4+ responders, as calculated by
percentage of proliferating Tresponder cells in co-cultures
divided by Tresponders alone, was significantly decreased in
SP participants compared with HD participants (p < 0.001)
(Fig. 4b). Calculation of the division index corroborated the
analysis shown in Fig. 4 using the percentage of cells divided
gate (data not shown). However, increased suppression of
CD4+ T cell activation, measured by both CD25 and
CD134, was observed at the higher Treg:Tresponder ratios
(Fig. 4c,d). Interestingly, Tregs from SP 606 (orange line)
suppressed CD4+ responders considerably more than the
Fig. 2 Predictive modelling using CITRUS confirms that increased Treg
frequency is a signature of slow progressors. Hierarchical gating (a–f) and
CITRUS analysis (g–k) was performed comparing SP participants and
matched HD participants on CD4+CD45RA− T cells. (a) Representative
plots of parent CD25+CD127lo Tregs and CD25loCD127+ T cell
populations. CD25+CD127lo Tregs were then enriched for CD39 and
FOXP3, followed by separation by HLA-DR and GITR expression,
emulat ing FlowSOM populat ions. (b) Summary graph of
CD25+CD127lo frequency in HD (black dots) and SP (blue dots)
groups and donor SP 606 (orange). (c–f) Boxplots for each
CD25+CD127loCD39+FOXP3+ and CD25loCD127+ gated subset; (c)
HLA-DRloGITR− (memory Treg_2), (d) HLA-DRintGITRlo (memory
Treg_3), (e) HLA-DRhiGITR+ (memory Treg_4), (f) HLA-DRhiGITR+
(HLA-DR+GITR+memory T cell). (g–i) CITRUS cluster spirals coloured
by (g) CD127, (h) CD25 and (i) FOXP3 expression intensity, with
clusters identified as different between the SP and HD cohorts
highlighted by arrows. (j) Boxplots to show relative abundance
(proportion) of CITRUS memory Treg_3 and memory Treg_4 in the
SP (blue dots) and HD (grey dots) groups. (k) Histograms show
phenotype of each cluster (pink) and relative expression of Treg
markers compared with background expression (blue); upper row,
memory Treg_3; lower row, memory Treg_4. Background relates to
expression of markers in all other clusters. *p < 0.05, **p < 0.01,
Wilcoxon matched-pairs signed rank test
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matched HD. Expression ratios for proliferation and activation
markers in individual SP participants, compared with the
matched HD participants, are shown in ESM Fig. 3b,
demonstrating that the differences are the result of an overall
pattern. No change was observed in the levels of activation via







































































































































































and proinflammatory cytokines), in the absence of Treg, in SP
compared with HD participants (ESM Fig. 3c).
Second, considering that the diminished suppression level
in slow progressors could be attributed to either reduced
suppressive ability of CD4+ Tregs or reduced responsiveness
of CD4+ Tresponders to suppression in the co-culture, we
performed allogeneic crossovers (Fig. 4e–h). We assessed
the suppressive ability of Tregs in co-cultures, with HD
responders and Tregs from the SP group. This revealed that
SP Tregs demonstrated significantly reduced suppression of
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Fig. 3 Increased GITR on memory Tregs in slow progressors compared
with healthy donors. Each memory CD4+ T cell metacluster (memory T
cell_1; memory T cell_2; memory T cell_3; CD49b+ memory T cell;
HLA-DR+GITR+ memory T cell; memory Treg_2; memory Treg_3;
memory Treg_4), from FlowSOM, was examined for a change in each
expression marker. (a, b) Expression heatmaps from the HD (a) and SP
(b) cohorts (SP 606 is not included). (c, d) FlowSOM GITR expression
concatenated from all HD (grey), all SP (blue) and SP 606 (orange) in the
memory Treg_4 metacluster, showing histograms (c) and summary graph
(d). Wilcoxon matched-pairs signed rank test, p < 0.07 (orange) all
donors included, p < 0.05 (blue) donor SP 606 and matched HD not
included in test. (e, f) GITR expression, from hierarchical gating,
concatenated from all HD (grey), all SP (blue) and SP 606 (orange) in
HLA-DRhiGITR+ Tregs showing histograms (e) and summary graph (f)
*p < 0.05, Wilcoxon matched-pairs signed rank test
Fig. 4 CD4+ Tregs from slow progressors have a reduced capacity to
control effector CD4+ T cells. The SP cohort is shown with blue lines and
dots, the HD cohort with black lines and dots, and the orange line/dots
represent donor SP 606. CD4+ T cells were sorted using a CD4+CD25+
Treg sorting kit. CD4+CD25− (responders) were CFSE-labelled and Tregs
were titrated at the observed ratios. Cells were activated with anti-CD3/28
beads and cultured for 3 days before flow cytometry. (a–d) Tregs cultured
with their CD4+ Tresponder counterparts (autologous) (e–h) HD, SP or SP
606 Tregs cultured with HD responders. (a, b and e, f) CFSE proliferation
(a, e) and percentage CFSE suppression (b, f). (c, d and g, h) Percentage
suppression of CD25 (c, g) and CD134 (d, h). Percentage suppression was
calculated using the positive control (activated responder cells with no
Tregs). *p < 0.05, **p < 0.01, ***p < 0.001, repeated measures two-way
ANOVA. †p < 0.05 Bonferroni’s post hoc multiple comparisons test
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1:60 Treg:Tresponder ratio (p = 0.07; p < 0.05 respectively),
compared with HD Tregs (Fig. 4f–g). Interestingly, this
reduced suppression could be overcome with an increased
Treg:Tresponder ratio, as demonstrated by no difference in
suppression at the higher Treg:Tresponder ratios. This indi-
cates that SP Tregs are impaired in their ability to suppress
CD4+ T cells, although an increase in frequency may over-
come this impaired suppression.
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Effector CD4+ T cells from slow progressors show increased
responses to Treg suppression Third, we assessed CD4+
Tresponders and their resistance to suppression. We
found that HD Tregs co-cultured with SP responders
suppressed CD4+ T cell proliferation similarly to HD
responders (Fig. 5a,b). However, suppression of CD25
and CD134 on SP CD4+ Tresponders was significantly
increased, compared with HD (Fig. 5c,d). Strikingly, CD4+
Tresponders from SP 606 (orange line) were more resistant
to suppression, as shown by CD25 (Fig. 5c) and CD134
measurement (Fig. 5d), compared with matched HD. To
confirm these observations, we analysed proinflammatory
cytokines IFNγ (Fig. 5e) and IL-17A (Fig. 5f). IFNγ
expression was significantly reduced in co-cultures of HD
Tregs with SP responders, compared with HD responders,
at a 1:60 Treg:Tresponder ratio. IL-17A production in the
co-cultures was variable; however, there was strikingly
elevated IFNγ and IL-17A in the co-cultures with SP 606
responders (orange dots), compared with the matched HD.
No significant differences in proinflammatory cytokines
Fig. 5 Effector CD4+ T cells are more responsive to suppression of T cell
activation in slow progressors. The SP cohort is shown with blue lines
and dots, the HD cohort with black lines and dots, and the orange
line/dots represent donor SP 606. CD4+ T cells were sorted using a
CD4+CD25+ Treg sorting kit. CD4+CD25− (responders) were CFSE-
labelled and Tregs were titrated at the observed ratios. Cells were activat-
ed with anti-CD3/28 beads and cultured for 3 days before flow cytometry
(CD25 counterstain) and cytokine analysis. HD Tregs were cultured with
either HD, SP or SP 606 responders. (a, b) CFSE proliferation (a) and
percentage CFSE suppression (b). (c, d) Percentage suppression of CD25
(c) and CD134 (d). Percentage suppression was calculated using the
positive control (activated responder cells with no Tregs). (e, f) IFNγ
expression (e) and IL-17A (f) in co-cultures. ***p < 0.001, **p <
0.01, repeated measures two-way ANOVA. †p < 0.05 Bonferroni’s post
hoc multiple comparisons test
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were observed when HD responders and SP Tregs were co-
cultured (ESM Fig. 4a). In autologous co-cultures, we
observed a modest decrease of IFNγ in each of the
Treg:Tresponder ratios assessed, and again a more variable
IL-17A production (ESM Fig. 4b). We found no differences
in IL-2 concentration between the HD and SP donors (data
not shown). Taken together, CD4+ Tregs from slow
progressors showed impaired suppressive capacity towards
effector CD4+ T cells; however, CD4+ effector T cells from
slow progressors were more responsive to Treg-mediated
suppression of T cell activation.
Discussion
Our findings demonstrate that individuals who have been
positive for multiple islet autoantibodies for 10 years or more,
and have not developed overt type 1 diabetes, have a unique
Treg signature. This signature is characterised by an increased
frequency of activated memory Tregs enriched with GITR
expression. However, surprisingly this is coupled with
impaired Treg function, in terms of effector CD4+ T cell
suppression. Conversely, effector CD4+ T cells in the slow
progressors are more responsive to suppression.
Our study also features a unique snapshot of a slowly
progressing individual (donor SP 606), assessed at a time of
raised HbA1c, and this individual’s response was different
from the others in the SP cohort. Therefore, we postulate that
the mechanisms protecting slow progressors might be lost as
they develop clinical symptoms of diabetes. Interestingly, no
loss of Treg function was observed in this individual, but the
effector CD4+ T cells were resistant to suppression of T cell
activation, which was accompanied by an increase in IFNγ
and IL-17 in Treg co-cultures. In terms of Treg numbers, this
former slow progressor maintained the increase in Treg
frequency but no enrichment of GITR expression.
Interestingly, the level of GITR expression on the memory
Treg_4 metacluster negatively correlated with HbA1c levels
measured in the SP cohort (data not shown), which should be
noted for future studies.
Functional Treg studies in type 1 diabetes cohorts have
demonstrated both impaired function in Tregs and a resistance
to suppression in effector T cells. Together, both are likely to
contribute to the impaired suppressive action, and a certain
level of heterogeneity may exist in individuals with type 1
diabetes [6, 17]. We demonstrate impaired Treg function in
parallel with an increased responsiveness to suppression in
slow progressors. However, impaired Treg function in slow
progressors could be overcome with an increase in the ratio of
Tregs to effector T cells. This suggests that the increase in
memory Tregs compensates for the impaired Treg function
observed in the SP cohort, and the potency of Treg suppres-
sion is dose dependent. It is also interesting that, in the donor
who had developed diabetes, this Treg impairment was not
observed, supporting the notion that there is heterogeneity;
however, we do not know if this individual had impaired
Treg suppression before diagnosis.
Equally, we find the opposite pattern with effector T
cells, with an increased response to suppression in slow
progressors, which was specifically linked with effector T
cell activation rather than proliferation, suggesting that
Tregs can differentially regulate CD4+ T cell activation.
The resistance to suppression in donor SP 606 was associ-
ated with an increase in proinflammatory cytokines, and
therefore, it is possible that Tregs were responding to proin-
flammatory cytokines with increased activity. This is
consonant with observations that, under certain circum-
stances, IFNγ is required for Treg-mediated suppression
[18]. Furthermore, Tregs may also contribute to the
increased IFNγ and IL-17A detected, as Tregs that are
Th1- and Th17-like have been identified [19], and these
Treg-produced proinflammatory cytokines may be required
for suppressive activity [19, 20]. It should be noted that we
did not observe any differences in IL-2 in Treg co-cultures
(or in CD25 [IL-2Rα] expression), which would suggest
that a lack of IL-2 production or competition for IL-2 was
not involved in the Treg impairment. The mechanism for
the increased sensitivity to suppression in the SP effector
CD4+ T cells was not addressed in this study. However, we
have previously demonstrated a decrease in CD95 expres-
sion on memory T cells [4], which may indicate an
increased resistance to cell death. The increased response
to suppression may be a global effector T cell feature in the
SP cohort, or specific to the naive or memory subset, and, in
our assays, the use of total effector CD4+CD25− T cells is a
limitation. Furthermore, Treg suppression assays in the
presence of antigen presenting cells (dendritic cells) will
provide further insight into slow progressor Treg function
[21]. Overall, our study highlights the crucial interplay
between Treg and effector T cells, and it will be important
to understand the role and timing of Treg dysfunction
during disease progression.
Unsupervised clustering revealed an increase in activat-
ed memory Tregs in slow progressors. Overall, Tregs in
type 1 diabetes cohorts are similar in frequency to control
individuals [17], although a reduction in activated FOXP3+
Tregs in type 1 diabetes has been reported [22]. Currently,
we cannot determine whether the subsets we have identi-
fied represent Tregs at differing points in maturity or
differentiation, or whether they are distinct subsets.
Furthermore, additional Treg markers may be required for
the identification of other Treg subsets [13] in this distinc-
tive cohort. Future transcriptomic and functional studies on
these Treg subsets would provide further insight, and it
would be interesting to study the Treg gene signature in
this SP group, which would provide a comparison with
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previous studies on both paediatric and adult new-onset
type 1 diabetes cohorts [23, 24].
We observed an increase in the expression of GITR, a
member of the TNF receptor (TNFR) family, in a distinct Treg
metacluster, in slow progressors. GITR expression, which is
frequently observed on activated Tregs [25] and is critical for
suppressive action in Tregs, was shown by the use of anti-GITR
antibodies [25, 26]. However, in some settings using anti-GITR
agonistic antibodies has not affected the suppressive ability of
Tregs, but rather induced proliferation and migration of patho-
genic T cells [27]. Indeed, reduced expression of GITR on Tregs
or a loss of GITR+ Tregs in individuals with type 1 diabetes does
not result in an impaired suppressive phenotype, but the Tregs
are more susceptible to apoptosis compared with those of
healthy donors [28]. In mouse models, GITR is crucial for
Treg expansion, as demonstrated both inGitr (Tnfrsf18)-knock-
out mice, which have a reduced Treg frequency [29], as well as
in Gitr-L (Tnfsf18)-deficient mice that demonstrate impaired
Treg expansion [30]. These studies suggest that increased
expression of GITR on Tregs in slow progressors may be the
result of an increased propensity to develop or expand. Further
functional studies are required to identify whether activated
memory GITR+ Tregs in slow progressors have an improved
survivalmechanism or a resistance to apoptosis. Considering the
importance of the GITR/GITR-L (GITR-ligand) pathway in
both effector T cells and Tregs, it is also important to identify
any difference in GITR-L signatures in immune cell compart-
ments known to express this ligand.
A limitation in this study was the relatively small number of
slow progressors available for study, but individuals followed for
islet autoantibody positivity for up to 32 years are rare. In addi-
tion, age-matched individuals with new-onset type 1 diabetes
were not included. It is a challenge tomatch our slow progressors
to people with new-onset diabetes, as they were considerably
older than many newly diagnosed individuals. For the future, it
would be beneficial to replicate our findings in additional slow
progressor cohorts, individuals with type 1 diabetes and individ-
uals positive for multiple islet autoantibodies, with the latter
allowing us to track and predict the individuals who will slowly
progress. Our study describes a rare case of the islet autoantibody
and Treg characteristics at diagnosis of type 1 diabetes in an
older adult. Furthermore, we identify an immune cell signature
in extreme slow progressors, and our study highlights the need to
develop our understanding of Treg heterogeneity that exists
during type 1 diabetes development, in order to help stratify
those who would benefit from regulatory T cell therapy.
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